Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.68 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.68 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.68 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714198 | 1.00 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503809 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503797 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL28083220 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL3371298 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503833 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503871 | 0.91 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL11119409 | 0.90 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Water SCHEMBL10710842 | 0.89 | CYP3A4 (0.66) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL11129611 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399402-B1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7115643-B2 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20040176432-A1 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-09-09 | — | — | US | disclosed |
| EP-1399402-A1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002498-A1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2003-01-09 | — | — | WO | disclosed |
| EP-0877739-B1 | AZOLE COMPOUNDS ENDOWED WITH ANTIMYCOTIC ACTIVITY FOR HUMAN AND VETERINARY USE | ZAMBON SPA (IT) | 2002-06-12 | — | — | EP | disclosed |
| US-6103909-A | EFFECTIVE AGAINST DRUG RESISTANT STRAINS OF CANDIDA, CRYPTOCOCCUS, ASPERGILLUS, FUSARIUM | ISAGRO S.P.A. AND ZAMBON GROUP S.P.A. (IT) | 2000-08-15 | — | — | US | disclosed |
| US-5869512-A | TREATING DRUG RESISTANT FUNGAL AND YEAST INFECTIONS | ZAMBON GROUP S.P.A (IT) | 1999-02-09 | — | — | US | disclosed |
| EP-0617031-B1 | Orally active azole derivates | URIACH & CIA SA J (ES) | 1998-09-16 | — | — | EP | disclosed |
| US-5760245-A | FUNGICIDES | J. URIACH & CIA S.A. (ES) | 1998-06-02 | — | — | US | disclosed |
| US-5646294-A | FUNGICIDES | J. URIACH & CIA. S.A. (ES) | 1997-07-08 | — | — | US | disclosed |
| US-5478826-A | Fungicides for human, animal and plants | J. URIACH & CIA. S.A. (ES) | 1995-12-26 | — | — | US | disclosed |
| EP-0617031-A1 | Orally active azole derivates | J. URIACH & CIA. S.A. (ES) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176432-A1 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | CYP51A1, MALT1, CYP7A1 | CYP3A4 42/4885CYP2C9 60/4885CYP2C19 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.